Artificial Intelligence | Machine Learning | Natural Language Processing Arpeggio | New Way to Discover Drugs


Enterprise, Drug Discovery, Pharmaceutical R&D, RNA Molecules, Drug-Resistant Cancer Boulder, Colorado, United States

Arpeggio

Artificial Intelligence | Machine Learning | Natural Language Processing


Arpeggio | New Way to Discover Drugs

Arpeggio

Drug Discovery, Pharmaceutical R&D, RNA Molecules, Drug-Resistant Cancer


Boulder, Colorado, United States

We apply high-throughput transcriptomics to match drugs to a disease based not just on a single target, but the biological network as a whole. Arpeggio embraces the complexity of biology by defining a drug's impact on hundreds of thousands of RNA molecules at once. This allows us to accurately predict whether a molecule could be an effective therapy. By scaling our transcriptomics platform, we're gearing up to accelerate the pace and efficiency of drug discovery and find new therapies for challenging diseases like drug-resistant cancer.

Every cell in our body contains the same DNA sequence, yet heart cells are very different from liver cells. This is due to thousands of differences in how these cells generate (or transcribe) RNA. With our growing RNA dataset, Arpeggio is learning connections between RNA expression, cell type, and disease. Many common diseases such as cancer and neurodegeneration are driven not just by dysfunction of a single gene but by the misregulation of hundreds or thousands of RNAs. At Arpeggio, we compare healthy and diseased cell states to identify RNA signatures that define disease. By identifying these RNAs we search for drugs that specifically reverse disease signatures. Arpeggio utilizes a unique technology called nascent RNA sequencing to measure RNAs directly affected by a compound treatment. This allows us to identify the primary effect of a drug on a cell and very quickly hone in on its mechanism. With new advances in next-generation sequencing and robotics, we're scaling our nascent RNA sequencing platform to test tens of thousands of compounds at a time. Arpeggio has built the world's largest database of nascent RNA sequences. For the first time, we are linking compound Structure-Activity Relationships with RNA fingerprints. Our database guides drug development by enabling predictions for whether a molecule will be toxic or impactful for a patient.

 

B2B

1 to 25

Funded

N/A

Scaling Up

2017

 
 

Healthcare
Biotechnology

Drugs that Specifically Reverse Disease
Effective Therapy

Increase Efficiency

 
 

Analytics
Service

Yes

Active

 
 

   Machine Learning
   Natural Language Processing


Drug Discovery

Drug Discovery


Image

Image

Video

Video

Text

Text

Structured

Structured

 

   Software


Python

Python

C/C++

C/C++

Pytorch

Pytorch

Flink

Flink

Typescript

Typescript

JavaScript

JavaScript

Redux

Redux

React

React


Machine Learning Algorithm

Machine Learning Algorithm

Deep Learning Algorithm

Deep Learning Algorithm

 
 

View All

Senior Scientist

Boulder, Colorado

Bioinformatician

Boulder, Colorado

 

AI/ML Professionals

Want to work at Arpeggio?

We can introduce you to the right person at Arpeggio

Talk to our Talent Team

 

12

1

$17M

Company was founded 2017 and it took almost 5 years (Sep 2022) to raise first external round

 
 

Date

Round

$ Raised

Investors

09/07/2022

Series A

$17M

Builders VC, Khosla Ventures, TechU Ventures, FundersClub, Alice Zhang, Fifty Years, Tencent, ATEM Capital, Formic Ventures, Tau Ventures, Milad Alucozai, Matthew De Silva

Date : 09/07/2022

Round: Series A

$ Raised: $17M

Investors: Builders VC, Khosla Ventures, TechU Ventures, FundersClub, Alice Zhang, Fifty Years, Tencent, ATEM Capital, Formic Ventures, Tau Ventures, Milad Alucozai, Matthew De Silva

 

Investors

Interested in researching Arpeggio?

We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Arpeggio

Request a Demo - Deal Souring Platform

 
Joey Azofeifa

Joey Azofeifa
Founder & CEO

Laura Norris

Laura Norris
COO & Co-founder

Robin Dowell

Robin Dowell
Co-Founder

Tim Read

Tim Read
Chief Technology Officer

Eric Martin

Eric Martin
Chief Scientific Officer

 
 

Potential Customers

Interested in what they do or partnership?

Learn more about how they work

Schedule a Call w/ Arpeggio